medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2018, Número 06

<< Anterior Siguiente >>

Ginecol Obstet Mex 2018; 86 (06)


Carcinogénesis de los tumores serosos del ovario: implicaciones quirúrgicas, avances recientes y futuros retos para su diagnóstico y tratamiento

Pérez-García GE, Sierra-Avendaño JA, Pérez-Barón MP, Álvarez-Ojeda OM

Idioma: Español
Referencias bibliográficas: 71
Paginas: 389-400
Archivo PDF: 534.83 Kb.


RESUMEN

Antecedentes: El cáncer de ovario es una importante causa de muerte de mujeres, responsable de 150,000 fallecimientos anuales en el mundo, con una supervivencia a 5 años inferior a 45%.
Objetivo: Exponer los avances en diagnóstico y tratamiento de la carcinogénesis de los tumores serosos ováricos y las repercusiones de los nuevos conceptos en el tratamiento clínico y quirúrgico.
Metodología: Estudio retrospectivo basado en la búsqueda sistemática de artículos con las palabras clave (MeSH): neoplasmas serosos de ovario, carcinogénesis, carcinoma seroso de bajo grado y carcinoma seroso de alto grado. La selección de los artículos estuvo a cargo, de forma independiente, de dos investigadores. De la misma forma dos patólogos evaluaron los artículos preseleccionados.
Resultados: Se seleccionaron y analizaron 66 artículos.
Conclusiones: Para la creación y adopción de estrategias en prevención primaria, diagnóstico y tratamiento de esta patología se requiere mayor comprensión de la fisiopatología y de los hallazgos encontrados en la última década, sobre todo los relacionados con las mutaciones en el gen BRCA, antecedentes familiares de tumores serosos del ovario, cáncer de mama o peritoneal de tipo epitelial, entre otras. La atención multidisciplinaria y actualizada repercutirá, significativamente, en la supervivencia de las pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Salazar H, Godwin AK, Daly MB, Paul B, Hogan WM, Rosenblum N, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst. 1996; 88(24):1810-20.

  2. World Cancer Research Foundation. Ovarian Cancer 2014 Report. 2014 (consultado 2017 Dic 2). http://www.aicr.org/continuousupdate- project/reports/ovarian-cancer-2014- report.pdf

  3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017; 41:3-14.

  4. Programa Nacional de Consensos Inter-Sociedades, Programa Argentino de Consensos de Enfermedades Oncológicas. Consenso Nacional Inter-Sociedades sobre Cáncer Epitelial de Ovario -Estadios Avanzados- y Tumores No Epiteliales de Ovario, 2014 (consultado 2017 Dic 5). http://www.sar. org.ar/web/docs/publica/ovario.pdf

  5. Cho K, Shih I. Ovarian cancer. Annu Rev Pathol. 2009; 1(4):287-313.

  6. Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34(3):433-43.

  7. Kurman RJ, Shih IM.. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016; 186:733-47.

  8. Rutgers JK, Lawrence WD. A small organ takes center stage: selected topics in fallopian tube pathology. Int J Gynecol Pathol. 2014; 33(4):385-92.

  9. Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol. 2010; 23(10):1316-24.

  10. Vang R, Shih I, Kurman RJ. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009; 16(5):267-82.

  11. Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, et al. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol. 2010; 118(3):299-302.

  12. Piek J, et al. Ovarian carcinogenesis, an alternative theory. Gynecologic Oncology 2007;107(2):355. https:// www.gynecologiconcology-online.net/article/S0090- 8258(07)00462-3/pdf

  13. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-18.

  14. Huang H, Chu S, Hsu C, Chen P, Ding D, Chang M, et al. Mutagenic, surviving and tumorigenic effects of follicular fluid in the context of p53 loss: initiation of fimbria carcinogenesis. Carcinogenesis. 2015; 36(11):1419-28.

  15. Huang H, Chu S, Hsu C, Chen P, Ding D, Chang M, et al. Haemoglobin in pelvic fluid rescues Fallopian tube epithelial cells from reactive oxygen species stress and apoptosis. J Pathol. 2016; 240(4):484-94.

  16. Lin S, Gerry E, Shih I. Tubal origin of ovarian cancer –the double-edged sword of haemoglobin. J Pathol. 2017; 242:3-6.

  17. Chene G, Lamblin G, Le Bail-Carval K, Chabert P, Bakrin N, Mellier G. Early preinvasive lesions in ovarian cancer. Biomed Res Int. 2014; 2014:639-52.

  18. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009; 3(2):165-70.

  19. Tang S, Onuma K, Deb P, Wang E, Lytwyn A, Sur M, et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol. 2012; 31(2):103-10.

  20. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP. A pathologist’s road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010; 17(5):293-302.

  21. Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the “sectioning and extensively examining the FIMbriated end” (SEE-FIM) protocol? Int J Gynecol Pathol. 2013; 32(4):353-7.

  22. Rivas-Corchado LM, González-Geroniz M, Hernández- Herrera RJ. Perfil epidemiológico del cáncer de ovario. Ginecol Obstet Mex. 2011; 79(9):558-64.

  23. Foulkes WD. Preventing ovarian cancer by salpingectomy. Curr Oncol. 2013; 20(3):139-42.

  24. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007; 31(2):161-9.

  25. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008; 26(25):4160-65.

  26. Lee Y, Miron A, Drapkin R, Nucci M, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211(1):26-35.

  27. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008; 109(2):168-73.

  28. Gómez-Pue D, Ibarrola-BuenAbad E, Lara-Núñez D, Vázquez-Alvarado P, Pérez-Quintanilla M. Salpingectomía como opción de reducción del riesgo de cáncer de ovario. Ginecol Obstet Mex. 2016; 84(9):614-19.

  29. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol. 2014; 4:21.

  30. Erickson BK, Conner MG, Landen CN. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013; 209(5):409-14.

  31. Chêne G, Penault-Llorca F, Raoelfils I, Bignon Y-J, Ray- Coquard I, Seffert P, et al. La cancérogenèse ovarienne: théories actuelles et passées. Gynécologie Obs Fertil. 2011; 39(4):216-23.

  32. Clarke BA, Branton PA, Henson DE, Nielsen ML, Ruby SG, Scully RE. Protocol for the examination of specimens from patients with carcinoma of the fallopian tube: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1999; 123(1):33-8.

  33. Rabban JT, Krasik E, Chen L-M, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009; 33(12):1878-85.

  34. Singh N, Gilks CB, Wilkinson N, Mccluggage WG. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014; 65(2):149-54.

  35. Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer. 2016; 55:38-46.

  36. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32.

  37. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460(3):237-49.

  38. Pons-Porrata LM, García-Gómez, Salmon-Cruzata A, Macías-Navarro MM, Guerrero-Fernández CM. Tumores de ovario: patogenia, cuadro clínico, diagnóstico ecográfico e histopatológico. MEDISAN. 2012; 16(6):920-31.

  39. Seidman, JD, Cho KR, Ronnett BM, Kurman R. Surface epitelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein’s Pathology of the Female Genital Tract. 6th ed. New York: Springer-Verlag, 2011;679-784.

  40. Li J, Ning Y, Abushahin N, Yuan Z, Wang Y, Wang Y, et al. Secretory cell expansion with aging: risk for pelvic serous carcinogenesis. Gynecol Oncol. 2013; 131(3):555-60.

  41. Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 2011; 3:625-34.

  42. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013; 24(Suppl 10):16-21.

  43. Gurung A, Hung T, Morin J, Gilks CB. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013; 62(1):59-70.

  44. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010; 29(3):203-11.

  45. Köbel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 2008; 10:e22.

  46. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15.

  47. Kohno M, Tanimura S, Ozaki K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull. 2011; 34(12):1781-84.

  48. Espinosa I, Catasus L, Canet B, D’Angelo E, Muñoz J, Prat J. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol. 2011; 24(6):846-54.

  49. Kleinberg L, Dong HP, Holth A, Risberg B, Trope' CG, Nesland JM, et al. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol. 2009; 40(6):795-806.

  50. West RB, van de Rijn M. Experimental approaches to the study of cancer-stroma interactions: recent findings suggest a pivotal role for stroma in carcinogenesis. Lab Invest 2007; 87:967-970.

  51. Chene G, Dauplat J, Radosevic-Robin N, Cayre A. Penault- Llorca F. Tu-be or not tu-be: that is the question… about serous ovarian carcinogenesis. Crit Rev Oncol Hematol. 2013; 88(1):134-43.

  52. Chêne G, Penault-Llorca F, Le Bouëdec G, Mishellany F, Dauplat MM, Tardieu AS, et al. Ovarian epithelial dysplasia: myth or reality? A review. Gynecol Obstet Fertil. 2008; 36(7-8):800-7.

  53. Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA1 or 2 genes? Rationale and preliminary development. Gynecol Oncol. 2011; 121(3):472-76.

  54. Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010; 34(10):1407-16.

  55. Oliver-Perez MR, Magriñá J, García AT, Jiménez-Lopez JS. Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: a reappraisal. Surg Oncol. 2015; 24(4):335-44.

  56. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007; 25(25):3985-90.

  57. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Clin Obstet Gynecol. 2007; 50(2):354-61.

  58. Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med. 2011; 171(8):760-68.

  59. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45(3):229-42.

  60. Bentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N, et al. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol. 2016; 27(11):1994-2004.

  61. Ditto A, Martinelli F, Bogani G, Lorusso D, Carcangiu M, Chiappa V, et al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. Gynecol Oncol. 2015; 138(1):78-82.

  62. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013; 121(1):14-24.

  63. Rocca WA,Grossardt BR, Maraganore DM. The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis. 2008; 5(3-4):257-60.

  64. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008; 70(3):200-9.

  65. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007; 69(11):1074-83.

  66. Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a populationbased cohort study. Eur Heart J. 2011; 32(6):745-50.

  67. Plusquin C, Fastrez M, Vandromme J, Rozenberg S. Factors affecting gynaecologists’ decision to perform prophylactic oophorectomy concomitantly with hysterectomy: a Belgian survey. Maturitas. 2011; 70(4):391-94.

  68. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014; 14:150.

  69. Palma-Ardiles G, Hernández-Fernández W, Gianuzzi X, Hernández A. Letter to the editor regarding the paper by Sang Hee Yoon et al. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer. 2016; 64:175-76.

  70. Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: a meta-analysis. Eur J Cancer. 2016; 55:38-46.

  71. Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol. 2017; 216(3):270.e1-270.e9 metadata.




2020     |     www.medigraphic.com